<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119819</url>
  </required_header>
  <id_info>
    <org_study_id>15062</org_study_id>
    <secondary_id>2013-003552-21</secondary_id>
    <secondary_id>I7I-MC-XNAA</secondary_id>
    <nct_id>NCT02119819</nct_id>
  </id_info>
  <brief_title>A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes</brief_title>
  <official_title>Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the safety and effectiveness of the study drug&#xD;
      known as LY2944876 to exenatide extended-release and placebo in participants with type 2&#xD;
      diabetes mellitus. All drugs will be given by an injection under the skin. Participants&#xD;
      remain on stable doses of metformin, as prescribed by their personal investigator if they&#xD;
      were on metformin at study entry. Participants' involvement in the study is expected to last&#xD;
      about 30 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include a 12 week blinded treatment period, where neither the participant nor&#xD;
      the investigator will know to which treatment each individual is assigned. Thereafter follows&#xD;
      a 12 week period where participants and the investigator will know which treatment they are&#xD;
      assigned to. Participants' on LY2944876 and on exenatide extended-release continue treatment&#xD;
      in this period, those who received placebo will be followed without treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Body Weight</measure>
    <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose</measure>
    <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
    <description>Least square means (LSM) was calculated from mixed-effects model with repeated measures (MMRM) analysis using restricted maximum likelihood (REML) with metformin use, baseline body mass index (BMI) category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values</measure>
    <time_frame>Baseline, Week (Wk) 12; Baseline, Week 24</time_frame>
    <description>SMBG 7-point profiles were measured at morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. LSM were calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipids</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from baseline in high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C). LSM was calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant an a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Fibroblast Growth Factor 21</measure>
    <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
    <description>LSM was calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Rescue Therapy</measure>
    <time_frame>Baseline through Therapy Completion (Week 24)</time_frame>
    <description>Participants who received rescue medication with non-study antihyperglycemic medications or change their stable dose of metformin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-Drug Antibodies to LY2944876</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Percentage of participants developing anti-drug antibodies to LY2944876.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2944876</measure>
    <time_frame>Baseline, Week 8, Week 12, Week 16, Week 20, Week 24</time_frame>
    <description>Evaluable pharmacokinetic concentrations from the specified timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2944876</measure>
    <time_frame>Baseline, Week 8, Week 12, Week 16, Week 20, Week 24</time_frame>
    <description>Evaluable pharmacokinetic concentrations from the specified timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adiponectin Levels</measure>
    <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
    <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Beta-Hydroxy Butyrate Levels</measure>
    <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
    <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glucagon Levels</measure>
    <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
    <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Levels</measure>
    <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
    <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>10 mg LY2944876</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.&#xD;
Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg LY2944876</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg LY2944876</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg LY2944876</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide extended-release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg exenatide extended-release given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.&#xD;
Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2944876</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>10 mg LY2944876</arm_group_label>
    <arm_group_label>15 mg LY2944876</arm_group_label>
    <arm_group_label>30 mg LY2944876</arm_group_label>
    <arm_group_label>50 mg LY2944876</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide extended-release</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Exenatide extended-release</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Oral</description>
    <arm_group_label>10 mg LY2944876</arm_group_label>
    <arm_group_label>15 mg LY2944876</arm_group_label>
    <arm_group_label>30 mg LY2944876</arm_group_label>
    <arm_group_label>50 mg LY2944876</arm_group_label>
    <arm_group_label>Exenatide extended-release</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women with diabetes mellitus Type 2&#xD;
&#xD;
          -  Have screening HbA1c ≥7.0% and ≤10.5% either on diet and exercise alone or on a stable&#xD;
             dose of metformin (≥1000 mg/day) for 3 months prior to screening&#xD;
&#xD;
          -  Have body mass index (BMI) ≥23 and ≤45 kilograms per meter squared at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of child bearing potential&#xD;
&#xD;
          -  Participants who have used thiazolidinediones within 3 months prior to screening, or&#xD;
             any other drugs for treatment of hyperglycemia (except metformin) within the prior 2&#xD;
             months&#xD;
&#xD;
          -  Participants who have used insulin for diabetic control for more than 6 consecutive&#xD;
             days within the prior year&#xD;
&#xD;
          -  Participants with impaired renal function (serum creatinine &gt;124 micromole per liter&#xD;
             (µmol/L) [1.4 milligrams per deciliter (mg/dL)] in women, &gt;133 µmol/L [1.5 mg/dL] in&#xD;
             men)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Muir Physician Network Clinical Research Center</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Endocrine, Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Group Inc</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M &amp; O Clinical Research, LLC</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Central Florida</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East West Medical Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iderc, P.L.C.</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Diabetes and Endocrinology Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern New Hampshire Diabetes and Endocrinology</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Corvallis Clinic P.C.</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blair Medical Associates, Inc.</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes and Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Gabriel Clinical Research</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakwell Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Health Associates, P.A.</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wade Family Medicine</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ampelokipoi</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31238</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampico</city>
        <zip>89000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdynia</city>
        <zip>81-553</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szczecin</city>
        <zip>70-506</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manati Medical Center</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Telemedicine Center</name>
      <address>
        <city>San Juan</city>
        <zip>00917-3104</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iaşi</city>
        <zip>700547</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ploiesti</city>
        <zip>100342</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Targu Mures</city>
        <zip>540098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Timisoara</city>
        <zip>300456</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2014</study_first_posted>
  <results_first_submitted>March 19, 2021</results_first_submitted>
  <results_first_submitted_qc>March 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2021</results_first_posted>
  <disposition_first_submitted>December 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 29, 2016</disposition_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.&#xD;
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>10 mg LY2944876</title>
          <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks, plus background PO metformin.</description>
        </group>
        <group group_id="P2">
          <title>15 mg LY2944876</title>
          <description>15 mg LY2944876 given SC once weekly for 24 weeks, plus background PO metformin..</description>
        </group>
        <group group_id="P3">
          <title>30 mg LY2944876</title>
          <description>30 mg LY2944876 given SC once weekly for 24 weeks, plus background PO metformin..</description>
        </group>
        <group group_id="P4">
          <title>50 mg LY2944876</title>
          <description>50 mg LY2944876 given SC once weekly for 24 weeks, plus background PO metformin..</description>
        </group>
        <group group_id="P5">
          <title>Exenatide Extended-release</title>
          <description>2 mg exenatide extended-release given SC once weekly for 24 weeks, plus background PO metformin..</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks,plus background PO metformin. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="70"/>
                <participants group_id="P5" count="69"/>
                <participants group_id="P6" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="62"/>
                <participants group_id="P6" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Jury Duty</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Left the city to get a job</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10 mg LY2944876</title>
          <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>15 mg LY2944876</title>
          <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>30 mg LY2944876</title>
          <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>50 mg LY2944876</title>
          <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Exenatide Extended-release</title>
          <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="73"/>
            <count group_id="B4" value="70"/>
            <count group_id="B5" value="69"/>
            <count group_id="B6" value="71"/>
            <count group_id="B7" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.1" spread="9.4"/>
                    <measurement group_id="B2" value="59.0" spread="8.5"/>
                    <measurement group_id="B3" value="56.1" spread="8.3"/>
                    <measurement group_id="B4" value="55.6" spread="8.4"/>
                    <measurement group_id="B5" value="57.6" spread="9.1"/>
                    <measurement group_id="B6" value="56.5" spread="9.7"/>
                    <measurement group_id="B7" value="57.1" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="199"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="47"/>
                    <measurement group_id="B7" value="264"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="59"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="348"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12</title>
        <description>HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline HbA1c data at Week 12. Missing observations are imputed using the Bayesian simple linear regression longitudinal model.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12</title>
          <description>HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.</description>
          <population>All randomized participants with baseline and at least one post-baseline HbA1c data at Week 12. Missing observations are imputed using the Bayesian simple linear regression longitudinal model.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.12"/>
                    <measurement group_id="O2" value="-1.09" spread="0.11"/>
                    <measurement group_id="O3" value="-1.44" spread="0.11"/>
                    <measurement group_id="O4" value="-1.33" spread="0.11"/>
                    <measurement group_id="O5" value="-1.42" spread="0.11"/>
                    <measurement group_id="O6" value="-0.29" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.459</p_value>
            <method>Bayesian</method>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.511</p_value>
            <method>Bayesian</method>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.988</p_value>
            <method>Bayesian</method>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-1.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.41</ci_lower_limit>
            <ci_upper_limit>-0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.934</p_value>
            <method>Bayesian</method>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-1.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>-0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.373</p_value>
            <method>Bayesian</method>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.433</p_value>
            <method>Bayesian</method>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.978</p_value>
            <method>Bayesian</method>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.904</p_value>
            <method>Bayesian</method>
            <param_type>Posterior Mean Difference</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at Week 24</title>
        <description>HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline HbA1c data at Week 24. Missing observations are imputed using the Bayesian simple linear regression longitudinal model.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 24</title>
          <description>HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.</description>
          <population>All randomized participants with baseline and at least one post-baseline HbA1c data at Week 24. Missing observations are imputed using the Bayesian simple linear regression longitudinal model.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.14"/>
                    <measurement group_id="O2" value="-1.14" spread="0.13"/>
                    <measurement group_id="O3" value="-1.37" spread="0.13"/>
                    <measurement group_id="O4" value="-1.29" spread="0.13"/>
                    <measurement group_id="O5" value="-1.48" spread="0.13"/>
                    <measurement group_id="O6" value="-0.38" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Body Weight</title>
        <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline data for body weight. Missing observations are imputed using the Bayesian simple linear regression longitudinal model.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Body Weight</title>
          <population>All randomized participants with baseline and at least one post-baseline data for body weight. Missing observations are imputed using the Bayesian simple linear regression longitudinal model.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="63"/>
                    <count group_id="O6" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.35"/>
                    <measurement group_id="O2" value="-1.86" spread="0.33"/>
                    <measurement group_id="O3" value="-2.01" spread="0.33"/>
                    <measurement group_id="O4" value="-3.23" spread="0.34"/>
                    <measurement group_id="O5" value="-2.04" spread="0.35"/>
                    <measurement group_id="O6" value="-1.22" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="0.47"/>
                    <measurement group_id="O2" value="-2.13" spread="0.45"/>
                    <measurement group_id="O3" value="-1.98" spread="0.45"/>
                    <measurement group_id="O4" value="-3.41" spread="0.46"/>
                    <measurement group_id="O5" value="-2.18" spread="0.47"/>
                    <measurement group_id="O6" value="-1.70" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose</title>
        <description>Least square means (LSM) was calculated from mixed-effects model with repeated measures (MMRM) analysis using restricted maximum likelihood (REML) with metformin use, baseline body mass index (BMI) category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.</description>
        <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline data for fasting blood glucose. Missing observations are imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose</title>
          <description>Least square means (LSM) was calculated from mixed-effects model with repeated measures (MMRM) analysis using restricted maximum likelihood (REML) with metformin use, baseline body mass index (BMI) category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.</description>
          <population>All randomized participants with baseline and at least one post-baseline data for fasting blood glucose. Missing observations are imputed using last observation carried forward (LOCF).</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.881" spread="4.618"/>
                    <measurement group_id="O2" value="-21.991" spread="4.371"/>
                    <measurement group_id="O3" value="-31.309" spread="4.305"/>
                    <measurement group_id="O4" value="-28.405" spread="4.506"/>
                    <measurement group_id="O5" value="-39.074" spread="4.419"/>
                    <measurement group_id="O6" value="-1.588" spread="4.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.497" spread="4.919"/>
                    <measurement group_id="O2" value="-30.186" spread="4.639"/>
                    <measurement group_id="O3" value="-29.875" spread="4.548"/>
                    <measurement group_id="O4" value="-31.390" spread="4.785"/>
                    <measurement group_id="O5" value="-40.328" spread="4.726"/>
                    <measurement group_id="O6" value="0.124" spread="4.973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values</title>
        <description>SMBG 7-point profiles were measured at morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. LSM were calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.</description>
        <time_frame>Baseline, Week (Wk) 12; Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline data for SMBG. Missing observations are imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values</title>
          <description>SMBG 7-point profiles were measured at morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. LSM were calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline fasting blood glucose as a covariate, and participant as a random effect.</description>
          <population>All randomized participants with baseline and at least one post-baseline data for SMBG. Missing observations are imputed using last observation carried forward (LOCF).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning pre-meal (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" spread="3.9"/>
                    <measurement group_id="O2" value="-28.4" spread="3.8"/>
                    <measurement group_id="O3" value="-34.3" spread="3.7"/>
                    <measurement group_id="O4" value="-34.8" spread="3.8"/>
                    <measurement group_id="O5" value="-38.7" spread="3.8"/>
                    <measurement group_id="O6" value="-7.4" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning pre-meal (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.5" spread="4.7"/>
                    <measurement group_id="O2" value="-29.1" spread="4.5"/>
                    <measurement group_id="O3" value="-29.6" spread="4.3"/>
                    <measurement group_id="O4" value="-34.2" spread="4.5"/>
                    <measurement group_id="O5" value="-36.8" spread="4.5"/>
                    <measurement group_id="O6" value="-14.4" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning 2 hours post-meal (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.9" spread="6.7"/>
                    <measurement group_id="O2" value="-34.2" spread="6.8"/>
                    <measurement group_id="O3" value="-36.0" spread="6.3"/>
                    <measurement group_id="O4" value="-26.4" spread="6.6"/>
                    <measurement group_id="O5" value="-43.5" spread="6.5"/>
                    <measurement group_id="O6" value="-1.5" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning 2 hours post-meal (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.9" spread="6.5"/>
                    <measurement group_id="O2" value="-35.9" spread="6.5"/>
                    <measurement group_id="O3" value="-37.1" spread="6.1"/>
                    <measurement group_id="O4" value="-42.8" spread="6.4"/>
                    <measurement group_id="O5" value="-42.7" spread="6.4"/>
                    <measurement group_id="O6" value="-6.3" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid-day pre-meal (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1" spread="5.1"/>
                    <measurement group_id="O2" value="-19.6" spread="5.1"/>
                    <measurement group_id="O3" value="-26.1" spread="4.8"/>
                    <measurement group_id="O4" value="-24.2" spread="5.0"/>
                    <measurement group_id="O5" value="-23.5" spread="5.0"/>
                    <measurement group_id="O6" value="-2.3" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid-day pre-meal (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" spread="5.6"/>
                    <measurement group_id="O2" value="-23.4" spread="5.6"/>
                    <measurement group_id="O3" value="-22.4" spread="5.3"/>
                    <measurement group_id="O4" value="-23.5" spread="5.4"/>
                    <measurement group_id="O5" value="-23.9" spread="5.5"/>
                    <measurement group_id="O6" value="-4.0" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid-day 2 hours post-meal (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1" spread="6.4"/>
                    <measurement group_id="O2" value="-20.7" spread="6.3"/>
                    <measurement group_id="O3" value="-24.6" spread="6.0"/>
                    <measurement group_id="O4" value="-22.2" spread="6.2"/>
                    <measurement group_id="O5" value="-27.4" spread="6.2"/>
                    <measurement group_id="O6" value="-8.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid-day 2 hours post-meal (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="6.1"/>
                    <measurement group_id="O2" value="-26.6" spread="5.9"/>
                    <measurement group_id="O3" value="-21.9" spread="5.7"/>
                    <measurement group_id="O4" value="-33.4" spread="5.9"/>
                    <measurement group_id="O5" value="-37.2" spread="5.9"/>
                    <measurement group_id="O6" value="-8.5" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening pre-meal (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.1" spread="5.3"/>
                    <measurement group_id="O2" value="-24.8" spread="5.2"/>
                    <measurement group_id="O3" value="-28.5" spread="4.9"/>
                    <measurement group_id="O4" value="-30.1" spread="5.1"/>
                    <measurement group_id="O5" value="-24.7" spread="5.1"/>
                    <measurement group_id="O6" value="-1.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening pre-meal (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.9" spread="5.7"/>
                    <measurement group_id="O2" value="-24.3" spread="5.6"/>
                    <measurement group_id="O3" value="-33.0" spread="5.3"/>
                    <measurement group_id="O4" value="-29.6" spread="5.4"/>
                    <measurement group_id="O5" value="-36.4" spread="5.6"/>
                    <measurement group_id="O6" value="-5.7" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening 2 hours post-meal (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.1" spread="5.9"/>
                    <measurement group_id="O2" value="-26.5" spread="5.7"/>
                    <measurement group_id="O3" value="-33.4" spread="5.4"/>
                    <measurement group_id="O4" value="-32.8" spread="5.7"/>
                    <measurement group_id="O5" value="-33.5" spread="5.7"/>
                    <measurement group_id="O6" value="4.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening 2 hours post-meal (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.2" spread="5.9"/>
                    <measurement group_id="O2" value="-27.9" spread="5.8"/>
                    <measurement group_id="O3" value="-26.0" spread="5.5"/>
                    <measurement group_id="O4" value="-37.2" spread="5.8"/>
                    <measurement group_id="O5" value="-36.9" spread="5.8"/>
                    <measurement group_id="O6" value="1.1" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.3" spread="5.7"/>
                    <measurement group_id="O2" value="-33.5" spread="5.8"/>
                    <measurement group_id="O3" value="-33.2" spread="5.8"/>
                    <measurement group_id="O4" value="-36.2" spread="5.6"/>
                    <measurement group_id="O5" value="-41.6" spread="5.7"/>
                    <measurement group_id="O6" value="5.6" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" spread="6.0"/>
                    <measurement group_id="O2" value="-25.4" spread="6.0"/>
                    <measurement group_id="O3" value="-32.3" spread="5.7"/>
                    <measurement group_id="O4" value="-38.5" spread="5.9"/>
                    <measurement group_id="O5" value="-42.9" spread="6.0"/>
                    <measurement group_id="O6" value="-6.9" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipids</title>
        <description>Change from baseline in high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C). LSM was calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant an a random effect.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline data for lipids. Missing observations are imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipids</title>
          <description>Change from baseline in high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C). LSM was calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant an a random effect.</description>
          <population>All randomized participants with baseline and at least one post-baseline data for lipids. Missing observations are imputed using last observation carried forward (LOCF).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="1.03"/>
                    <measurement group_id="O2" value="0.92" spread="0.98"/>
                    <measurement group_id="O3" value="0.90" spread="0.96"/>
                    <measurement group_id="O4" value="1.04" spread="1.01"/>
                    <measurement group_id="O5" value="2.35" spread="0.990"/>
                    <measurement group_id="O6" value="2.17" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="4.37"/>
                    <measurement group_id="O2" value="-1.12" spread="4.16"/>
                    <measurement group_id="O3" value="-1.46" spread="4.09"/>
                    <measurement group_id="O4" value="-5.11" spread="4.24"/>
                    <measurement group_id="O5" value="-0.12" spread="4.22"/>
                    <measurement group_id="O6" value="7.32" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.63" spread="11.49"/>
                    <measurement group_id="O2" value="-13.32" spread="10.93"/>
                    <measurement group_id="O3" value="-15.40" spread="10.59"/>
                    <measurement group_id="O4" value="-20.96" spread="11.16"/>
                    <measurement group_id="O5" value="-11.83" spread="11.01"/>
                    <measurement group_id="O6" value="10.61" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="3.75"/>
                    <measurement group_id="O2" value="-0.40" spread="3.57"/>
                    <measurement group_id="O3" value="-0.24" spread="3.56"/>
                    <measurement group_id="O4" value="-0.04" spread="3.72"/>
                    <measurement group_id="O5" value="0.37" spread="3.65"/>
                    <measurement group_id="O6" value="4.55" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Fibroblast Growth Factor 21</title>
        <description>LSM was calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
        <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline data for fasting fibroblast growth factor 21. Missing observations are imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Fibroblast Growth Factor 21</title>
          <description>LSM was calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
          <population>All randomized participants with baseline and at least one post-baseline data for fasting fibroblast growth factor 21. Missing observations are imputed using last observation carried forward (LOCF).</population>
          <units>microgram per liter (µg/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.071"/>
                    <measurement group_id="O2" value="0.06" spread="0.068"/>
                    <measurement group_id="O3" value="-0.03" spread="0.068"/>
                    <measurement group_id="O4" value="-0.14" spread="0.069"/>
                    <measurement group_id="O5" value="-0.09" spread="0.069"/>
                    <measurement group_id="O6" value="-0.11" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.071"/>
                    <measurement group_id="O2" value="-0.04" spread="0.068"/>
                    <measurement group_id="O3" value="-0.07" spread="0.067"/>
                    <measurement group_id="O4" value="-0.12" spread="0.070"/>
                    <measurement group_id="O5" value="-0.06" spread="0.069"/>
                    <measurement group_id="O6" value="-0.09" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Rescue Therapy</title>
        <description>Participants who received rescue medication with non-study antihyperglycemic medications or change their stable dose of metformin.</description>
        <time_frame>Baseline through Therapy Completion (Week 24)</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline data for participants requiring rescue therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Rescue Therapy</title>
          <description>Participants who received rescue medication with non-study antihyperglycemic medications or change their stable dose of metformin.</description>
          <population>All randomized participants with baseline and at least one post-baseline data for participants requiring rescue therapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="4.3"/>
                    <measurement group_id="O5" value="2.9"/>
                    <measurement group_id="O6" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Developing Anti-Drug Antibodies to LY2944876</title>
        <description>Percentage of participants developing anti-drug antibodies to LY2944876.</description>
        <time_frame>Week 12 and Week 24</time_frame>
        <population>All randomized participants who received study drug and had evaluable immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Developing Anti-Drug Antibodies to LY2944876</title>
          <description>Percentage of participants developing anti-drug antibodies to LY2944876.</description>
          <population>All randomized participants who received study drug and had evaluable immunogenicity.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.6"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="63"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2944876</title>
        <description>Evaluable pharmacokinetic concentrations from the specified timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.</description>
        <time_frame>Baseline, Week 8, Week 12, Week 16, Week 20, Week 24</time_frame>
        <population>All randomized participants who received study drug LY2944876 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2944876</title>
          <description>Evaluable pharmacokinetic concentrations from the specified timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.</description>
          <population>All randomized participants who received study drug LY2944876 and had evaluable PK data.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="607" spread="282"/>
                    <measurement group_id="O2" value="799" spread="368"/>
                    <measurement group_id="O3" value="1690" spread="732"/>
                    <measurement group_id="O4" value="2570" spread="1240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2944876</title>
        <description>Evaluable pharmacokinetic concentrations from the specified timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.</description>
        <time_frame>Baseline, Week 8, Week 12, Week 16, Week 20, Week 24</time_frame>
        <population>All randomized participants who received study drug LY2944876 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2944876</title>
          <description>Evaluable pharmacokinetic concentrations from the specified timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.</description>
          <population>All randomized participants who received study drug LY2944876 and had evaluable PK data.</population>
          <units>nanograms*hour per milliliter (ng*h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88100" spread="40600"/>
                    <measurement group_id="O2" value="117000" spread="50800"/>
                    <measurement group_id="O3" value="247000" spread="106000"/>
                    <measurement group_id="O4" value="381000" spread="187000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adiponectin Levels</title>
        <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
        <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline data for adiponectin levels. Missing observations are imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adiponectin Levels</title>
          <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
          <population>All randomized participants with baseline and at least one post-baseline data for adiponectin levels. Missing observations are imputed using last observation carried forward (LOCF).</population>
          <units>µg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.168"/>
                    <measurement group_id="O2" value="0.03" spread="0.160"/>
                    <measurement group_id="O3" value="-0.10" spread="0.157"/>
                    <measurement group_id="O4" value="0.12" spread="0.161"/>
                    <measurement group_id="O5" value="0.04" spread="0.160"/>
                    <measurement group_id="O6" value="0.03" spread="0.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.245"/>
                    <measurement group_id="O2" value="0.30" spread="0.226"/>
                    <measurement group_id="O3" value="0.28" spread="0.221"/>
                    <measurement group_id="O4" value="0.58" spread="0.235"/>
                    <measurement group_id="O5" value="0.14" spread="0.231"/>
                    <measurement group_id="O6" value="0.25" spread="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Beta-Hydroxy Butyrate Levels</title>
        <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
        <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline data for beta-hydroxy butyrate levels. Missing observations are imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Beta-Hydroxy Butyrate Levels</title>
          <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
          <population>All randomized participants with baseline and at least one post-baseline data for beta-hydroxy butyrate levels. Missing observations are imputed using last observation carried forward (LOCF).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.13"/>
                    <measurement group_id="O2" value="-0.28" spread="0.12"/>
                    <measurement group_id="O3" value="-0.13" spread="0.12"/>
                    <measurement group_id="O4" value="-0.31" spread="0.12"/>
                    <measurement group_id="O5" value="-0.29" spread="0.12"/>
                    <measurement group_id="O6" value="-0.23" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.11"/>
                    <measurement group_id="O2" value="-0.39" spread="0.10"/>
                    <measurement group_id="O3" value="-0.34" spread="0.10"/>
                    <measurement group_id="O4" value="-0.33" spread="0.10"/>
                    <measurement group_id="O5" value="-0.19" spread="0.10"/>
                    <measurement group_id="O6" value="-0.37" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glucagon Levels</title>
        <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
        <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline data for glucagon levels. Missing observations are imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucagon Levels</title>
          <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
          <population>All randomized participants with baseline and at least one post-baseline data for glucagon levels. Missing observations are imputed using last observation carried forward (LOCF).</population>
          <units>picomol per liter (pmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="0.82"/>
                    <measurement group_id="O2" value="-2.65" spread="0.79"/>
                    <measurement group_id="O3" value="-5.14" spread="0.79"/>
                    <measurement group_id="O4" value="-6.21" spread="0.81"/>
                    <measurement group_id="O5" value="-1.58" spread="0.79"/>
                    <measurement group_id="O6" value="-0.04" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="1.15"/>
                    <measurement group_id="O2" value="-2.25" spread="1.05"/>
                    <measurement group_id="O3" value="-4.40" spread="1.05"/>
                    <measurement group_id="O4" value="-4.93" spread="1.11"/>
                    <measurement group_id="O5" value="-0.19" spread="1.08"/>
                    <measurement group_id="O6" value="0.66" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Levels</title>
        <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
        <time_frame>Baseline, Week 12; Baseline, Week 24</time_frame>
        <population>All randomized participants with baseline and at least one post-baseline data for insulin levels. Missing observations are imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2944876</title>
            <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2944876</title>
            <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>30 mg LY2944876</title>
            <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2944876</title>
            <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Exenatide Extended-release</title>
            <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Levels</title>
          <description>LSM are calculated from MMRM analysis using REML with metformin use, baseline BMI category, baseline HbA1c category, country, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline parameter result as a covariate, and participant as a random effect.</description>
          <population>All randomized participants with baseline and at least one post-baseline data for insulin levels. Missing observations are imputed using last observation carried forward (LOCF).</population>
          <units>micro-international units/milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="1.21"/>
                    <measurement group_id="O2" value="0.97" spread="1.13"/>
                    <measurement group_id="O3" value="0.03" spread="1.14"/>
                    <measurement group_id="O4" value="0.96" spread="1.17"/>
                    <measurement group_id="O5" value="2.78" spread="1.14"/>
                    <measurement group_id="O6" value="-0.85" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="1.51"/>
                    <measurement group_id="O2" value="0.68" spread="1.39"/>
                    <measurement group_id="O3" value="0.58" spread="1.40"/>
                    <measurement group_id="O4" value="0.34" spread="1.48"/>
                    <measurement group_id="O5" value="1.97" spread="1.40"/>
                    <measurement group_id="O6" value="1.45" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All randomized participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>10 mg LY2944876</title>
          <description>10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>15 mg LY2944876</title>
          <description>15 mg LY2944876 given SC once weekly for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>30 mg LY2944876</title>
          <description>30 mg LY2944876 given SC once weekly for 24 weeks.</description>
        </group>
        <group group_id="E4">
          <title>50 mg LY2944876</title>
          <description>50 mg LY2944876 given SC once weekly for 24 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Exenatide Extended-release</title>
          <description>2 mg exenatide extended-release given SC once weekly for 24 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Branchial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="7" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="35" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" events="24" subjects_affected="15" subjects_at_risk="71"/>
                <counts group_id="E3" events="45" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E4" events="25" subjects_affected="12" subjects_at_risk="70"/>
                <counts group_id="E5" events="52" subjects_affected="18" subjects_at_risk="69"/>
                <counts group_id="E6" events="16" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E2" events="33" subjects_affected="21" subjects_at_risk="71"/>
                <counts group_id="E3" events="53" subjects_affected="20" subjects_at_risk="73"/>
                <counts group_id="E4" events="90" subjects_affected="32" subjects_at_risk="70"/>
                <counts group_id="E5" events="55" subjects_affected="17" subjects_at_risk="69"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" events="21" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E4" events="37" subjects_affected="22" subjects_at_risk="70"/>
                <counts group_id="E5" events="12" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E5" events="14" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

